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ABSTRACT 
Background: Nitroglycerin (also known as glyceryl trinitrate (GTN)), a vasodilator best known for 
treatment of ischemic heart disease, has also been investigated for its potential therapeutic benefit in 
ischemic stroke. The completed Efficacy of Nitric Oxide in Stroke trial suggested that GTN has 
therapeutic benefit with acute (within 6 hours) transdermal systemic sustained release therapy. 
Objective: To examine an alternative use of GTN as an acute therapy for ischemic stroke following 
successful recanalization. 
Methods: We administered GTN IA following transient middle cerebral artery occlusion in mice. 
Because no standard dose of GTN is available following emergent large vessel occlusion, we 
performed a dose–response (3.12, 6.25, 12.5, and 25 µg/µL) analysis. Next, we looked at blood 
perfusion (flow) through the middle cerebral artery using laser Doppler flowmetry. Functional 
outcomes, including forced motor movement rotor rod, were assessed in the 3.12, 6.25, and 12.5 
µg/µL groups. Histological analysis was performed using cresyl violet for infarct volume, and glial 
fibrillary activating protein (GFAP) and NeuN immunohistochemistry for astrocyte activation and 
mature neuron survival, respectively. 
Results: Overall, we found that acute post-stroke IA GTN had little effect on vessel dilatation after 15 
min. Functional analysis showed a significant difference between GTN (3.12 and 6.25 µg/µL) and 
control at post-stroke day 1. Histological measures showed a significant reduction in infarct volume 
and GFAP immunoreactivity and a significant increase in NeuN. 
Conclusions: These results demonstrate that acute IA GTN is neuroprotective in experimental 
ischemic stroke and warrants further study as a potentially new stroke therapy. 
 
INTRODUCTION 
Stroke, disruption of blood flow to the brain due to vascular occlusion (ischemic) or bleeding 
(hemorrhagic), is the second leading cause of death worldwide and a leading cause of long-term 
disability.1 Emergent large vessel occlusion (ELVO) is the most life-threatening and disabling type of 
ischemic stroke. Treatment options for ELVO consist of endovascular thrombectomy (ET) and/or IV 
tissue plasminogen activator (t-PA), but not all patients are eligible owing to exclusion criteria.2–4 
Furthermore, while ET and IV t-PA have improved patient survival, there is a need for adjunctive 
therapies to be used in tandem with or as a standalone treatment following successful vessel 
recanalization.5 Any potential pharmacotherapy administration may be most successful and cause 
fewer systemic side effects if it is targeted at the site of ischemia. We hypothesize that improved 
treatment for ELVO might include rapid recanalization of the occluded vessel via ET combined with 
directed acute pharmacotherapy. To test such a targeted therapeutic approach, our laboratory uses an 
IA experimental model of pharmacotherapy administration in combination with transient tandem 
ipsilateral common carotid artery (CCA) and middle cerebral artery (MCA) occlusion, hereafter 
referred to as MCA occlusion (MCAo).6 
Using the already exposed vasculature of the MCAo, we can selectively administer our preferred drug 
IA, further mimicking the human clinical condition of pharmacotherapy delivery. Combining the two 
methods allows us to mimic an acute ischemic stroke but also guarantee successful recanalization 
followed by drug delivery in a timely manner similar to ET. Thus far, we have successfully applied 
this experimental therapeutic approach to the administration of verapamil, demonstrating an 86% 
reduction in infarct volume and significant increase in functional outcome.5 These results led us to 
conclude that selectively administering verapamil IA was safe and neuroprotective. 
In this study, we chose to investigate the therapeutic potential of acute IA administration of 
nitroglycerin (glyceryl trinitrate (GTN)) in our experimental stroke model. GTN is a Food and Drug 
Administration approved vasodilator (angina pectoris, high blood pressure) that was recently studied 
in the Efficacy of Nitric Oxide in Stroke (ENOS) ischemic stroke clinical trial.7–9 That study 
investigated the potential of GTN to reduce blood pressure and improve functional outcome following 
acute ischemic stroke with treatment through a systemic sustained release transdermal patch. Results 
showed a reduction in blood pressure on poststroke days (PSDs) 1 and 7 but no improvement in 
functional outcome at day 90.7-9, 10 Individuals with a stroke are at an increased risk of increased 
intracranial pressure; a reduction in intracranial pressure either through direct (IA) or indirect (patch) 
administration to the cerebrovasculature could improve outcome.11 The ENOS trial acutely reduced 
blood pressure and by doing so it was hoped that it would have a neuroprotective effect but it failed to 
show improvement beyond blood pressure reduction. These results could be directly tied to GTN’s 
short half-life and inability to reach the cerebrovasculature if applied as a patch on the arm or chest. 
 
MATERIAL AND METHODS 
Experiments were performed in accordance with the Institutional Animal Care and Use Committee at 
the University of Kentucky and ARRIVE (Animal Research: Reporting of In Vivo Experiments) 
guidelines.12 In short, 16-week-old C57/Bl6 (25–30 g) male mice ( Jackson Laboratories) were given 
GTN (American Reagents) diluted in vehicle (water 39.5%, ethyl alcohol 30%, propylene glycol 
30%) or vehicle only IA 5 min following transient MCAo. Animals were randomly grouped into 
naïve (age-matched littermate controls), control (MCAo surgery with IA injection of vehicle through 
the internal carotid artery (ICA)), and treated (MCAo surgery with IA injection of 3.12, 6.25, 12.5, 25 
and 50 µg/µL GTN through the ICA). Increasing doses of GTN were administered to determine safety 
and efficacy, as there is no standard dose of IA GTN. Previous flow rate and injection volume studies 
determined the optimal flow rate of 2.5 µL/min and injection volume of 10 µL per mouse.6 All 
subjects were treated in a blinded fashion and exclusion criteria were as follows: rupture of the 
MCA/CCA during stroke surgery, inability to place tubing in the external carotid artery (ECA), 
leakage of tubing around the ECA upon pumping, failure of the animal to recover from surgery 
resulting in death, death of the animal during the study, and signs of haemorrhage upon brain 
extraction (five animals were excluded based on these criteria). Our MCAo and IA model of 
pharmacotherapy administration has a mortality rate of <5%.6 
Animal number 
The experiment was conducted using 50 animals (five groups); naïve animals were excluded from 
laser Doppler and MouseOx studies. For laser Doppler and MouseOx (n=5/group), infarct volume 
measurements (n=10/group), functional outcome assessment (n=6/group), blood draws (control n=5, 
treated n=2), and brain immunohistochemistry (n=5/group). 
Vital sign measurements 
Physiological measurements (heart rate (bpm)) and blood pressure (pulse distention (mm)) were taken 
on animals undergoing only the IA surgery (no MCAo surgery) over a 20 min period, beginning at the 
IA injection and continuous through 20 min. Measurements were taken using the MouseOx Plus 
(Starr Life Science), where a thigh sensor was placed on the shaved left thigh of an anesthetized 
mouse. 
Perfusion 
Blood flow through the MCA was measured using the laser Doppler Periflux System 5000 with a 2 
mm tip (Perimed). Blood flow measurements were taken before and after occlusion and 15 min after 
IA injection (IA injection occurs following reperfusion). 
Middle cerebral artery occlusion and intra-arterial injection 
Animals were anesthetized using a ketamine/xylazine mixture for the MCAo and IA injection 
procedure. Transient focal cerebral ischemia was induced using our previously described method.5 6 13 
14 MCAo occlusion was for 1 hour with pre-/post-occlusion and recanalization confirmed by laser 
Doppler flowmetry. Body temperature was measured using the MouseOx Plus (rectal thermometer) 
and maintained with a heating pad.  
GTN IA injection followed our previously published protocol.5 6 In brief, a midline incision was made 
from mandible to sternum exposing and isolating the CCA, ECA, and ICA. The ECA was 
permanently occluded with suture at its distal end and the ICA was temporarily occluded. Using a pair 
of microscissors, a small nick was made in the ECA midway between the CCA bifurcation and the 
proximal suture. Micro-angio tubing was inserted into the ECA through the nick and placed at the 
bifurcation and suture was used to secure the tubing into the ECA. After removing occlusion of the 
MCA, CCA and ICA flow was restored and the vessel was allowed to recanalize for 5 min. At that 
time, GTN or vehicle was injected via the IA route.5 6 Once the injection was complete the ECA was 
permanently occluded at its proximal end with a third suture and the animal was sutured closed. 
Behavioral testing 
Animals were subjected to rotor rod to determine functional ability following surgery and 
pharmacotherapy administration. Animals were trained for 3 days before stroke surgery and tested 3 
days following stroke surgery. Rotor rod was used to determine the percentage change from baseline 
over a 5 min interval with an accelerating rod from 0 to 40 rpm for three trials.  
Infarct volume 
On PSD 7 mice were euthanized via cervical dislocation, the whole brain was removed and flash 
frozen, sectioned on a cryostat (20 mm), and stained using cresyl violet. Infarct volume was analyzed 
from scanned cresyl violet sections with Image J software (NIH).5 
Blood draws 
To measure nitric oxide (NOx) levels in the blood, submandibular blood draws were performed 1 day 
before stroke (baseline), 15 min after IA injection, and PSD 1. In short, animals were placed in the 
dorsal position with their head tilted exposing the submandibular vein region.15 A 5 mm Goldenrod 
animal lancet was used to pierce the submandibular vein, blood (10% of the total animal blood 
volume) was collected into K2-EDTA tube, and centrifuged at 14 000 rpm for 15 min. Plasma was 
collected and analyzed for NOx levels. 
NOx analysis 
Nitrate reductase was used to reduce nitrate to nitrite in blood plasma samples. A volume of 5 mL 
nitrate reductase and 5 mL of co-factor (Nitrite/Nitrate Assay Kit, Sigma-Aldrich, UK) was added to 
40 mL plasma and incubated for 2 hours at 25°C. Nitrate/nitrite (NOx) concentrations were then 
determined using Sievers Nitric Oxide Analyzer (NOA 280i; GE Instruments, UK). During this 
procedure the nitrite was reduced to nitric oxide by acetic acid. Nitric oxide was then quantified using 
ozone-chemiluminescence technology. 
Immunohistochemistry 
Whole brains flash frozen were sectioned on a cryostat (Leica) at 20 mm and mounted on slides. Glial 
fibrillary activating protein (GFAP 1:500 antibody dilution, Sigma) immunohistochemistry was used 
to evaluate astrogliosis, and NeuN (1:500 antibody dilution, Abcam) immunohistochemistry was used 
to analyze mature neuron survival in the stroke-affected region (core and penumbra). Infarct and peri-
infarct regions (defined as a 500mm boundary extending from the edge of the infarct core, medial and 
lateral to the infarct) of the cortex were identified histologically after cryostat sectioning. Stains were 
imaged with a Nikon Eclipse Ti microscope and images collected with a charge coupled device 
(CCD) camera and Nikon NIS Element BR software. Photoshop software was used to analyze 
positive pixel density of sectioned brains from naïve, control, and treated groups. 
Statistical analysis 
Measured variables are shown as mean±SEM. Analysis of results for comparison between treatment 
groups (infarct volume, immunohistochemistry) was performed using Student’s t test. Time course 
comparisons (behavior) and NOx were analysed using a two-way repeated measures analysis of 
variance. We defined significance as *p≤0.05, **p≤0.01, and ***p≤0.001. 
Compliance with STAIR criteria 
To maximize the applicability of our results, we designed the study with reference to the Stroke 
Treatment Academic Industry Roundtable (STAIR) recommendations for preclinical neuroprotection 
research.16 We also performed a dose–response study to determine if there was a deleterious dose, and 
found that all animals survived IA GTN injections. 
 
RESULTS 
Vital sign measurements 
Physiological measurements for heart rate (IA injection only) demonstrated no difference from 
baseline for all groups except the 6.25 µg/µL GTN group, which showed a significant reduction in 
beats per minute from immediately after IA to 15 min after IA, though these animals recovered 
without incident despite a lowered heart rate. Pulse distention showed no difference between groups 
from baseline with all animals recovering without incident. Data not shown. 
Perfusion 
Perfusion measurements using the laser Doppler were made at baseline, occlusion, and 15 min after 
IA to determine whether IA GTN had any effect on the MCA perfusion. We demonstrated an 83% 
reduction in cortical blood flow through the MCA after occlusion. After removal of the occlusion and 
5 min recanalization, GTN and vehicle were administered IA and blood flow was measured 15 min 
after IA. While all groups increased perfusion through the MCA there was no significant difference 
between GTN doses and vehicle over the time period analyzed (figure 1A). 
Infarct volume 
Infarct volume (figure 1B) was assessed using cresyl violet (figure 1C) and analyzed on PSD 7 using 
Image J. Mean infarct volumes (mm3) demonstrated a dose–response effect compared with control, 
with 12.5 µg/µL GTN showing a significant decrease in infarct volume. However, the 25 µg/µL dose 
showed signs of hemorrhage and an infarct volume similar to control. 
Behavioral testing 
In addition to infarct volume assessment, we performed rotor rod functional analysis on all of the 
groups except the less well-tolerated 25 µg/µL dose. Functional assessment of IA GTN on the rotor 
rod was measured as the percentage change from baseline on PSDs 1, 3, and 7 (figure 2). On PSD 1 
the control stroke group showed a decrease from baseline (−27.25±13.42) as expected with injury, 
while the naïve group without any brain injury continued to improve on the task (21.10±31.43) as 
expected. GTN doses of 3.12 and 6.25 µg/µL showed a significant improvement (23.48±35.30 and 
30.51±25.06, respectively) compared with control, while the 12.5 µg/µL GTN dose was only slightly 
less than baseline (−7.36±24.52). On PSD 3, the control group was still reduced from baseline 
(−12.65±32.51) and the GTN dose of 3.12 µg/µL (20.75±19.04) remained above baseline but was 
slightly less than PSD 1 measurements. GTN group 6.25 µg/µL (36.73±27.2) continued to improve 
from baseline and PSD 1 measurements, and 12.5 µg/µL (51.77±32.29) improved significantly from 
PSD 1 measurements. On PSD 7, the control group remained below baseline levels (−26.11±26.88). 
However, the GTN dose of 3.12 µg/µL (10.51±22.91) remained above baseline measurements but 
was slightly less than its PSD 1 and 3 measurements and the 6.25 µg/µL (35.59±26.63) and 12.5 
µg/µL (32.34±37.79) GTN doses continued to improve from baseline and their PSD 1 values. 
Nevertheless, none of the GTN dose measurements were significantly greater than the control by PSD 
7. 
Blood nitric oxide measurements 
As one of the goals of the IA administration of GTN after stroke was to limit systemic effects, we 
investigated whether such IA GTN administration had any effect on blood NOx levels. Compared with 
baseline, blood NOx levels were elevated 15 min after either IA injection or GTN treatment, the latter 
being slightly, but not significantly, more elevated. By PSD 1, blood NOx remained similarly elevated 
from baseline levels in both groups (figure 3). 
Immunohistochemistry 
Antibodies specific to proteins associated with mature neuron survival (NeuN) and astrocytic 
activation (GFAP) were used (figure 4). Compared with control, GTN treated animals showed a dose–
response stair step effect with a significant increase in NeuN positive pixels at doses 3.12, 6.25, and 
12.5 µg/µL. Likewise, a similar stair step dose–response was seen in GFAP, with control having a 
significantly increased number of GFAP positive pixels compared with GTN doses 6.25 and 12.5 
µg/µL. 
 
DISCUSSION 
Currently, IV t-PA is the only approved pharmacotherapy available but extensive exclusion criteria 
limit its use to less than 16% of those affected by stroke. With the recently completed and successful 
ET trials for ELVO, ET can be used to rapidly recanalize stroke through IA access. This provides a 
clinical/translational opportunity to co-administer potentially neuroprotective compounds. Using a 
clinically relevant mouse model of stroke (MCAo), we have developed a new method of IA (similar 
to ET) pharmacotherapy delivery that allows us to deliver a selected compound directly to the site of 
ischemia while mitigating systemic side effects.5 
GTN was used in the recently completed ENOS trial and shown to be safe when administered in patch 
form following stroke. The outcome of the trial was an acute reduction in blood pressure, but no 
improvement in functional outcome.9–11 GTN is a known vasodilator and is commonly used to treat 
ischemic heart disease, but we and others believe it may also have significant neuroprotective 
properties as discussed below. Therefore, our goal in this study was to target GTN directly at the site 
of the stroke via our IA model following MCAo to evaluate these potentially neuroprotective 
properties. 
Since no standard IA dose of GTN is available we started with a dose–response evaluation (3.12, 
6.25, 12.5, and 25 µg/µL) to determine if IA GTN was safe (no bleeding into the parenchyma) and 
had an effect on infarct volume. Our study showed that the mice tolerated and survived IA GTN with 
no overt deleterious effects, and there was a positive dose-dependent effect on infarct volume with a 
significant reduction noted with the 12.5 µg/µL dose. However, the 25 µg/µL dose resulted in 
bleeding into the ventricles and an infarct volume similar to control. Therefore, we conclude that IA 
GTN is a potentially safe neurotherapeutic with a specific toxicity profile, which includes 
intraventricular hemorrhage at the highest dose tested. Additional studies should further delineate the 
most effective dose. 
We evaluated the potential effect of IA GTN on functional outcome. Although the lower doses (3.12 
and 6.25 µg/µL) initially had significant positive effects immediately following infarct induction on 
PSD 1, dose–response effects were no longer observed by PSD 7 (though functional outcome was still 
improved compared with controls). This may be due, in part, to GTN’s very short half-life (1.5–7.5 
min) such that noted beneficial effects on infarct volume and neuronal viability (and decreased 
reactive gliosis) were not sufficiently pervasive to result in long-term functional benefit. In further 
support of such a conclusion, one potential mediator of GTN neuroprotection, NOx (discussed 
elsewhere in greater detail17–19 and below), also has an extremely short half-life of 2–6 s. We expect 
that further studies with post-stroke IA GTN, or perhaps combining IA GTN with other longer lasting 
potentially neuroprotective agents using multiple assessment tools, may demonstrate functional 
benefits. 
Although we saw no effects of IA GTN on animal pulse distention, we further examined potential 
systemic effects from IA GTN administration by measuring post-stroke blood NOx levels at several 
points after IA GTN or vehicle administration. NOx is a good measure of IA GTN administration 
because GTN is converted to NOx by endothelial nitric oxide synthetase and released into the blood 
stream from the vascular endothelium. Ultimately, we noted a transient, but insignificant increase in 
blood NOx levels with IA GTN treatment. These results are consistent with efficacious GTN delivery 
and suggest a potential mechanism of action, while simultaneously further demonstrating a relative 
lack of systemic effects with IA GTN treatment. 
It has been known for decades that GTN has both neuroprotective and neurotoxic properties, 
depending upon whether it is present in physiologic or pathologic concentrations, respectively. Post-
stroke GTN-mediated neuroprotection may result from vasodilatation of the effected vasculature, 
which leads to increased blood flow and return of nutrients. NOx has been shown to be 
neuroprotective through vessel dilatation, antiapoptotic mechanisms as a reactive oxygen species 
scavenger, and through inhibition of lipid peroxidation sustaining cellular membrane integrity. In our 
study, we noted transient, but insignificant increases in both MCA vasodilatation and blood NOx 
levels with IA GTN treatment. The mechanism of action of IA GTN may be a combined effect 
(vasodilatation and production of nitric oxide species), but one additional possibility is that IA GTN 
might have increased local NOx levels in the stroke-targeted brain; this analysis should be performed 
in additional studies. Collectively, despite the limitations of this study, our results suggest a new 
therapeutic modality of GTN which, independent of its blood-pressure-lowering effects, might be of 
benefit after ischemic stroke. 
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FIGURES 
 
Figure 1 (A) Blood perfusion measurements as percentage change from baseline for combined groups 
(black dot), control (red line), 3.12 µg/µL (green line), 6.25 µg/µL (gray line), and 12.5 µg/µL (blue 
line) at baseline (0–5 min), post-occlusion (5 min after occlusion), and post-IA injection (15 min after 
IA injection). Combined (N=30), control (n=5), 3.12 µg/µL (n=5), 6.25 µg/µL (n=5), and 12.5 µg/µl 
(n=5). (B) Infarct volume analysis of control versus GTN doses (3.12, 6.25, 12.5, and 25 µg/µL). (C) 
Cresyl violet image for control, 3.12 µg/µL, 6.25 µg/µL, 12.5 µg/µL, and 25 µg/µL group (n=10 per 
group). *p<0.05; **p<0.001. GTN, glyceryl trinitrate. 
 
 Figure 2 Rotor rod behavioral measurements: control (black), naïve (red), 3.12 µg/µL (green), 6.25 
µg/µL (gray), and 12.5 µg/µL (blue). Rotor rod forced motor movement percentage change from 
baseline; groups were trained and combined for baseline measurements. Groups were separated after 
stroke surgery into control, naïve, and GTN treated and were tested on PSD 1, 3, and 7 (n=6 per 
group). */#p<0.05. GTN, glyceryl trinitrate; PSD, post-stroke day. 
 
 
Figure 3 Nitric oxide (NOx) blood concentrations for control versus GTN (12.5 µg/µL) treated on 
post-IA and day 1. Treated (n=2), control (n=5). GTN, glyceryl trinitrate. 
 
 Figure 4 Graphs and images for immunohistochemistry, magnification at 20× with quantification of 
positive pixel density. (A) Graph depicting positive pixel for GFAP control versus GTN-treated doses 
in infarcted region with representative images. (B) Graph depicting positive pixels for NeuN stain for 
control versus GTN treated doses in infarcted region with representative images (n=5 per group). 
Scale bar=100 μm. *p<0.05; **p<0.001; ***p<0.0001. GFAP, glial fibrillary activating protein; 
GTN, glyceryl trinitrate. 
